4.5 Article

Efficacy and Safety of Voriconazole Versus Amphotericin B Deoxycholate Induction Treatment for HIV-Associated Talaromycosis: A Prospective Multicenter Cohort Study in China

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Infectious Diseases

HIV-associated talaromycosis: Does timing of antiretroviral therapy matter?

Yuanyuan Qin et al.

Summary: This study aimed to evaluate the optimal timing of antiretroviral therapy (ART) initiation for HIV-positive patients with talaromycosis. The results showed that patients who initiated ART early had lower mortality rates and lower rates of AIDS-defining events or death compared to those who deferred ART initiation.

JOURNAL OF INFECTION (2022)

Article Mycology

Voriconazole Versus Amphotericin B as Induction Therapy for Talaromycosis in HIV/AIDS Patients: A Retrospective Study

Weie Huang et al.

Summary: This retrospective study compared the efficacy and safety of voriconazole and dAmB as induction therapy for HIV-associated disseminated talaromycosis. Voriconazole showed similar response rates with shorter durations of induction antifungal therapy and hospital stay, indicating its potential as a better choice in clinical practice. Few adverse reactions occurred in either the voriconazole or dAmB group, suggesting both drugs are safe options for treatment.

MYCOPATHOLOGIA (2021)

Article Medicine, General & Internal

A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis

Thuy Le et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Review Pharmacology & Pharmacy

Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity

Richard J. Hamill

Article Public, Environmental & Occupational Health

Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients

Khuanchai Supparatpinyo et al.

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2007)